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Abstract
Background: Most health care providers do not treat tobacco dependence routinely. This may in part be due to the
treatment “default.” Current treatment guidelines recommend that providers (1) ask patients if they are willing to quit
and (2) provide cessation-focused medications and counseling only to smokers who state that they are willing to quit.
The default is that patients have to “opt in” to receive cessation assistance: providers ask smokers if they are willing to
quit, and only offer medications and cessation support to those who say “yes.” This drastically limits the reach of cessation
services because, at any given encounter, only one in three smokers say that they are ready to quit. The objective of this
study is to determine the impact of providing all smokers with tobacco-cessation treatment unless they refuse it (OPT
OUT) versus current practice—screening for readiness and only offering treatment to smokers who say they are ready to
quit (OPT IN).
Methods: This individually randomized clinical trial is conducted in a tertiary-care hospital. We will conduct the trial
among up to 1000 randomly selected hospitalized smokers to determine the population impact of changing the
treatment default, identify mediators of outcome, and determine the cost-effectiveness of this new, highly proactive
approach. This is a population-based study that targets an endpoint of vital interest; applies minimal eligibility criteria
to broaden generalizability; and utilizes hospital staff for interventions to ensure long-term sustainability. The study
employs delayed consent and an innovative Bayesian adaptive design to evaluate a major shift in our approach to
care. If effective, this change would expand the reach of tobacco-cessation treatment from 30% to 100% of smokers.
Discussion: Regardless of outcome, the trial will provide a model of how to alter and evaluate the impact of health
care defaults. If OPT OUT proves to be more effective, it will expand the population eligible for cessation treatment by
over 300%. It will also simplify the tobacco-cessation treatment algorithm, and relieve busy health care providers of the
burden of evaluating readiness to quit.
Trial registration: Clinical Trials Registration, ID: NCT02721082. Registered on 22 March 2016.
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Background
Based on current rates of tobacco use uptake and cessa-
tion, 20 million Americans will die from tobacco-related
illnesses between 2000 and 2050 [1]. Due to the 20–40-
year time lag between starting smoking and the onset of
tobacco-related illnesses [2], helping smokers quit is the
best way to immediately reduce illness and deaths.
Guideline-based tobacco-cessation treatment consists of
two branching approaches [3]: motivational counseling,
based on the principles of Motivational Interviewing [4],
for patients not willing to make a quit attempt; and
cessation-oriented pharmacotherapy and counseling for
smokers who are prepared to make a quit attempt. Mo-
tivational treatment focuses on building smokers’ motiv-
ation to quit, but its effectiveness for smoking cessation
is, at best, mixed [5].
Cessation-oriented pharmacotherapy and counseling
double quit rates over no-treatment controls [3, 6], but
the “default option” for patients unwilling to quit tobacco
use is “no treatment.” With each step of guideline-based
tobacco-cessation treatment, smokers must say “yes” (are
they willing to quit, do they want medications, do they
want counseling) in order to receive evidence based
care—they must “opt in.” This is in stark contrast to
treatment of other common medical conditions, such as
hypertension, where the default option is “treatment”:
physicians identify and initiate treatment for hypertension
[7], and patients must “opt out” if they do not want care.
Likely as a result of this tobacco-cessation treatment “de-
fault,” fewer than one in five smokers actually get assistance
in quitting on any given outpatient encounter with their
health care providers [8–10]. In hospitals, an even smaller
percentage of smokers receive assistance: a meta-analysis
found that only 14% of inpatient smokers were provided
with a prescription for cessation medication and 12%
received referrals for follow-up [11]. Moreover, because
smokers must opt in for cessation counseling and medica-
tion separately, few receive both components of evidence-
based care [12]. Many would blame this treatment gap on
smokers and their lack of motivation to quit smoking.
Another potential cause, however, is how the “default”
treatment for tobacco dependence is currently constructed
in US health care systems.
The treatment default for tobacco is different from any
other chronic health condition. In health care, most treat-
ment guidelines direct clinicians to provide evidence-
based treatment, which the patient will receive by default
unless they refuse treatment. In fact, this choice architec-
ture is arguably the most ethical. Where there is strong
clinical evidence that supports an appropriate therapy, the
therapy should be presented as the default [13]. Hence,
the exceptional position that smokers should be asked if
they are “willing” to quit creates a rate-limiting step in
tobacco-cessation treatment that may be less effective and
less ethical than an opt-out approach. Details on how
defaults potentially affect treatment choices, and how this
relates to tobacco-cessation treatment, may be found in a
commentary by Richter and Ellerbeck [14].
Decision theorists suggest that institutions should struc-
ture default choices to be the options that make the
choosers better off, as judged by themselves [15]. Tobacco-
cessation treatment is an excellent candidate for a default
that favors treatment because 70% of smokers state that
they ultimately want to quit smoking [12]. Choosing to quit
in the near future, however, is extremely difficult for
smokers because they get the pleasures of smoking, and the
pain of abstaining from smoking in the present, but suffer
the terrible consequences of smoking in the future [16].
This may be why fewer smokers state that they are ready to
quit in the near future. They could use a “nudge” to accept
treatment in order to reach their ultimate goal of quitting.
In our opinion, smokers fail to receive effective cessation
treatment due to the way in which the US structures the
tobacco-cessation treatment default [14]. In this study, we
will examine the effects of proactively providing cessation-
oriented treatment to all smokers, regardless of their
willingness or readiness to quit.
The objective of the study is to determine the impact
of providing all smokers with cessation pharmacotherapy
and counseling unless they refuse it (OPT OUT) versus
current practice—screening for readiness and only
offering cessation assistance to smokers who say they
are ready to quit (OPT IN).
Methods
Design and setting
The study is a prospective, randomized, comparative
effectiveness study using a Bayesian adaptive design. It is
a two-arm study with individual randomization to
groups in a large Midwestern academic medical center
(Fig. 1). The hospital is a 475-bed tertiary-care hospital
that admits over 20,000 patients per year and is located
in a large metropolitan area. The study was approved by
the University of Kansas Human Subjects Committee
(IRB00006196; STUDY00001774)
Study procedures
The study employs a modified Zelen design for consent
[17, 18]. Study staff will select, randomize, and intervene
with patients prior to collecting verbal consent at the 1-
month post-discharge visit. For the outcome analysis, the
study uses a Bayesian adaptive trial design [19]. Mediation
analyses will also provide insight into why changing the
default did, or did not, work. We hypothesize that smoker
perceptions of what course of action their cessation
counselor recommends, and what is the status quo for re-
ceiving medications and counseling at the hospital, will
affect their counseling participation, medication use, and
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quit rates (Fig. 1). The trial will be implemented in four
stages over 4.5 years (Table 1).
Recruitment of study participants
Random selection for the trial via the electronic health
record (EHR)
Study staff have access via the EHR to a real-time, com-
prehensive list of all smokers in the hospital—the to-
bacco use list. For the purposes of the study, research
staff will randomly select patients from the tobacco use
list, and provide selected patients’ names to study staff
for baseline assessment, randomization, and interven-
tion. Random selection of participants serves two pur-
poses. First, it ensures that we will test the change of
default among a sample representative of all hospitalized
smokers, which will enhance the generalizability of the
findings. Second, it ensures that smokers not seeking
tobacco-cessation treatment will be included in the trial,
which will enhance our ability to detect the effect of
changing the default among smokers who have not
requested, and who might not be considered “ready” for
medications and counseling.
Patients excluded from random selection via EHR
A number of hospital services routinely do not permit a
majority of their patients to be placed on Nicotine
Replacement Therapy (NRT). These include the operat-
ing room, orthopedic surgery, gastro-intestinal surgery,
the burns service, and the neurology stroke service.
Patients on these units, as well as patients less than
18 years of age, patients who have been in the hospital
longer than 3 days, and pregnant patients, will be
excluded from the tobacco use list prior to random
selection for the trial. Patients who requested, or have
orders for, tobacco-cessation treatment will be treated as
usual by the existing hospital tobacco-cessation treat-
ment service and will only be included in the trial if ran-
domly selected.
Eligibility and baseline assessment
Study staff will visit all randomly selected smokers. For
all study patients, staff will assess and address patient
comfort, provide brief advice to quit, and provide a quit-
smoking pamphlet. Staff will then assess eligibility and
collect baseline data. Initial study eligibility criteria in-
clude: (1) the ability to speak English or Spanish, (2)
have no significant comorbidity that precludes participa-
tion (i.e., acute, life-threatening illness or altered mental
status such as dementia), (3) be a permanent resident of
the state of Kansas or Missouri, (4) provide a secondary
telephone contact to ensure 1-month follow-up survey
completion, and (5) completed all eligibility questions.
Other eligibility criteria ensure that patients are able to
benefit from the intervention. Because follow-up counsel-
ing is by telephone, participants are required to have
access to a telephone or mobile phone. Because patients
are receiving free starter packs of NRT and prescriptions
for post-discharge smoking cessation medications, eligibil-
ity is limited to patients who smoke one or more
Fig. 1 Theoretical model
Table 1 Clinical trial timeline




• 400 participants consented • 6-month
outcome data collected on 200 participants
• Manuscript on study design under review
24–39 2: Implementation • Baseline data collected on 800 participants
• 6-month data collected on 600 of
participants • Data cleaned and prepared
for analysis on half of all participants
40–51 3: Early analyses • Complete consent of final 200 participants
by midyear • 6-month data collection
completed on all participants • Manuscripts




• All data cleaned and prepared for analysis
• Conduct all outcome, mediator/moderator
analyses • Manuscripts on study outcomes
under review
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cigarettes per day, have smoked at least 25 of the past
30 days, and are otherwise medically eligible to use NRT
(i.e., no acute myocardial infarction/ST-elevation myocar-
dial infarction (STEMI), or other acute heart conditions).
Last, several criteria preserve our ability to detect the
effects of the trial. Patients cannot already have been
seen by hospital tobacco-cessation treatment (UKan-
Quit) counselors or study staff during the recruitment
hospitalization, cannot currently be taking cessation
medications, or cannot be enrolled in a separate quit-
smoking program.
Study staff will record eligibility for the study on their
clinic service tablet computer, along with standard service
administrative data, which includes demographics, smok-
ing characteristics, readiness to quit, and contact informa-
tion for the 1-month follow-up. These administrative data
will constitute baseline data for the clinical trial.
The patients who are not eligible will be provided with
the typical hospital tobacco-cessation services but will not
be enrolled into the trial. The typical hospital services will
follow the guidelines of UKanQuit [20], which is a dedi-
cated tobacco-cessation treatment service funded by the
hospital. UKanQuit services include: (1) working with the
medical team to address inpatient withdrawal symptoms,
usually with NRT, (2) assessing readiness to quit, (3)
providing motivational counseling to smokers who are not
ready to quit, and (4) arranging for post-discharge coun-
seling and medication prescriptions for patients who are
ready to quit. The principal investigator (PI) of the present
study also directs UKanQuit, and staff for both projects
will work together closely to ensure that the study and the
UKanQuit service avoid duplicating intervention among
the same patients.
Enrollment and random allocation
All patients who are eligible will be automatically en-
rolled into the trial and randomly allocated to a treat-
ment arm. Consent for the trial is delayed—it is sought
at the 1-month follow-up. A function will be pro-
grammed into the tablet intake form so that study staff
will select a key to randomize eligible smokers to either
OPT OUT or OPT IN. At the beginning of the trial, the
function will assign patients to groups in a 1:1 allocation
ratio. Later, based on intermediate outcomes, the study
biostatistician may alter the ratio in accordance with the
Bayesian study design (see “Data analysis,” below). Study
staff will offer smokers motivational counseling, medica-
tions, and cessation-oriented practical counseling in
accordance with the study arm to which patients are
randomized. Patients are only randomized into our trial
once. If someone has been randomized into the trial in
the past—regardless of whether they provided consent at
the 1-month follow-up or not—they are not eligible for
repeat randomization. There are likely cases where a
randomly selected patient is screened and found ineli-
gible at one point in time, then eligible at a later
readmission date. These patients may be enrolled at the
later admission date.
Rationale for conducting a study with delayed consent
The study uses a modified Zelen design, in which con-
sent is obtained after randomization and treatment. We
considered consenting patients before randomization
and treatment. This would, however, require patients to
“opt in” to being in a trial and possibly exclude the very
smokers who might benefit from changing the default.
We rejected consent before randomization and treat-
ment, as it is the very experimental manipulation we
seek to test. The Zelen design, in which patients are
consented after randomization, can markedly enhance
recruitment and improve generalizability by including a
higher proportion of eligible patients [21, 22]. In a de-
parture from most traditional Zelen design trials, the
proposed study will delay consent until after treatment
in order to examine the impact of OPT OUT on cessa-
tion at 1-month post discharge.
OPT IN and OPT OUT intervention procedures—framing the
default
We have created language that constitutes the “choice
architecture” for each study condition (Table 2). We
have crafted these phrases to be short and simple, to en-
able study staff to reliably use them. Based on the pa-
tients’ group assignment, staff will frame the default and
provide the appropriate intervention.
Inpatient counseling and treatment plan—OPT OUT
For all patients in OPT OUT, staff will provide brief
practical counseling, complete a treatment plan, and
provide a pamphlet that outlines tips on quitting. The
treatment plan includes: (1) inpatient medications, (2)
outpatient prescription for medication and a free “starter
pack” of medications, and (3) post-discharge counseling.
In describing the treatment plan for the patients, study
staff operationalize constructs thought to underpin the
power of the default [23]. These terms: (1) signal the
provider’s positive attitude towards medication and
counseling, and (2) state that the hospital’s status quo is
to provide medications and counseling.
Using this OPT OUT language, staff will clearly indi-
cate that they believe medications and counseling will
benefit the patient, and that the hospital routinely and
proactively provides cessation-oriented care to smokers.
Unless a patient “opts out” of any or all elements of the
treatment plan, all patients will receive all elements of
the treatment plan, including inpatient medications, out-
patient prescription and starter pack, and post-discharge
counseling calls.
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Inpatient counseling and treatment plan—OPT IN
For patients in OPT IN, staff will screen for willingness
to stay having quit after leaving the hospital. Patients
who are willing to quit will be offered similar counseling,
treatment planning, and medications as patients in OPT
OUT, including a pamphlet with tips on quitting.
However, instead of proactively providing these services,
staff will ask patients if they would like each element of
the treatment plan—post-discharge counseling and/or
post-discharge prescription for medication. Patients will
only receive the elements of care to which they opt in.
Patients in OPT IN who are not willing to quit will
receive brief intervention, in accordance with current
treatment guidelines. This consists of a four-page pamph-
let with resources for quitting and a brief counseling
session that addresses the “5 Rs” of motivational counsel-
ing (Relevance, Risks, Rewards, Roadblocks, Repetition) [3].
Post-discharge treatment—OPT OUT—counseling
All patients in OPT OUT will be enrolled in post-
discharge counseling that will be delivered by study staff.
Participants who accept enrollment into counseling
services will receive up to four proactive counseling calls
in each of the 4 weeks following discharge. Each call is de-
signed to provide practical counseling to help participants
develop problem-solving and coping skills, secure social
support, and design a plan for successful cessation and
long-term abstinence. Initial calls last approximately
30 min and follow-up calls last on average 15 min. Once
participants quit smoking, counselors review high-risk
situations, coping skills, and stress management to pre-
vent relapse. When participants “slip,” counselors trouble-
shoot relapse situations and encourage smokers to quit
again. We will use RedCAP to store data for all calls,
including number of attempts to reach the smoker, num-
ber of calls completed, and duration of calls.
Post-discharge treatment—OPT OUT—medication
prescription and NRT “starter pack”
Study staff will work with all patients in OPT OUT to select
a long-term cessation medication and plan how they will
obtain and fill prescriptions post discharge. Study staff will
request a prescription for post-discharge cessation medica-
tion via a note in the patients’ medical record, and via a text
message to the floor pharmacist assigned to the patients’
medical team. The patients’ hospital physician will make the
final determination regarding whether to write a cessation
medication prescription, and which medication to prescribe.
To ensure that patients leave the hospital with some
form of cessation medication, in order to avoid relapse,
study staff will provide all OPT-OUT patients with a 2-
week starter pack of over-the-counter quit-smoking medi-
cations. This will include 14 days of combination nicotine
replacement pharmacotherapy, consisting of 14 nicotine
patches plus 14-day supplies of either (a) nicotine gum, or
(b) nicotine lozenges. The choice of the short-acting NRT
will be made based on contraindications, past history of
success/failure, and personal preferences [3]. On the day
of hospital discharge, study staff will provide the sealed
starter pack to the patient at the bedside, for the patient to
use once they leave the hospital.
Post-discharge treatment—OPT IN—counseling and
medications
Study staff will provide OPT-IN patients who “opted in”
to post-discharge counseling the same counseling that is
Table 2 Treatment options by study arm
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provided to OPT-OUT patients. Likewise, for OPT-IN
patients who want a prescription for post-discharge
medications, study staff will arrange for a prescription
and provide a starter pack in the same manner as these
elements are provided to OPT-OUT patients.
Month-1 call for service data collection and informed
consent
In accordance with standard procedures in the existing
UKanQuit treatment program [20, 24], study staff will
call all patients at 1 month post enrollment to assess
outcomes including smoking status, quit attempts, coun-
seling utilization, medication use, and other factors
related to quitting (see Table 3, Core study measures).
At the close of the call, study staff will verbally debrief
patients on their inclusion in the trial and invite them to
participate in the study. Study staff will collect additional
data related to study outcomes.
Rationale for measuring main outcome at 1 month post
intervention
The present study is focused on how best to engage
smokers in tobacco-cessation treatment (i.e., counseling
and medications) and quit. Assessing outcomes at 1 month
will best capture the immediate impact of OPT IN versus
OPT OUT on medication/counseling use, quit attempts,
and abstinence [25, 26]. Moreover, assessing outcomes at
1 month is in accordance with Joint Commission
Guidelines and UKanQuit standard practice for post-
discharge follow-up of hospitalized smokers [27]. Perhaps
most importantly, 1 month represents an important time-
frame for hospitals, as hospitals with excessive 1-month
readmission rates for selected diagnoses will receive de-
creased Medicare reimbursements [28]. Should our inter-
vention prove effective, it could pave the way for future
studies on the impact of smoking cessation on reduced
30-day readmission rates for specific diagnoses. Those
who refuse consent at 1 month will not be eligible for
inclusion again into the trial and they will be included
(simply counted as smokers, because we will have no data
on them) in our simplified intent-to-treat (ITT) analyses.
Reimbursement
Patients who participate and complete the 1-month survey
will be reimbursed US$25 whether or not they consent to
participate in the clinical trial. Study staff will reimburse
patients who consent to participating in the clinical trial
and completing the extended 1-month survey with an
additional US$25. All reimbursements will be via reload-
able debit cards. The debit cards utilize the MasterCard
payment system and are accepted at virtually every institu-
tion that accepts a credit card. Participants will also be
reimbursed US$25 for the 6-month follow-up survey and
US$50 for each salivary cotinine sample returned.
Project measures (Table 3)
Tobacco abstinence
Outcome measures are adapted from the Society for
Research on Nicotine and Tobacco’s Workgroup on
Abstinence Measures and Workgroup on Biochemical
Verification [29, 30]. Our primary endpoint is 7-day, veri-
fied cigarette abstinence at 1 month after enrollment.
Subjects with missing data will be counted as smokers.
Verification of abstinence
We will use either mailed salivary cotinine or in-person
carbon monoxide (CO) testing to confirm smoking sta-
tus. Participants who report 7-day point-prevalence
abstinence, and who are not taking NRT, will be asked
to provide a saliva sample. Cotinine is the measure of
choice because of its sensitivity and specificity [30].
Samples will be stored in a − 20 °C freezer until labora-
tory analysis. Participants who are still using NRT, or
who refuse salivary cotinine, will be verified via CO test-
ing. Those with < 10 ppm will be considered abstinent.






7-day point-prevalence abstinence ✓ ✓
Biochemical quit verification ✓ ✓






Medication use/adherence ✓ ✓
Sociodemographics/mediators/moderators
Demographics: age, gender, race ✓
Length of hospital stay (for index visit) ✓
Reason for hospitalization (index visit) ✓
Readiness to quit, craving/withdrawal ✓ ✓












Nicotine Replacement Therapy (NRT)
(calculated from patient self-reported use)
✓ ✓
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Secondary outcomes, mediators, and moderators
Study counselors will track counseling data, which will be
summarized as “total counseling time” for analyses. We will
assess the type, the dose, and the number of days of medi-
cation was used via the method of Williams et al. [31, 32].
This will be summarized as “number of days of medication
use” for analyses. Default-related variables are derived from
the academic literature on choice theory and include
smokers’ perceptions of provider attitudes toward tobacco-
cessation treatment (implied recommendation), smokers
perceptions of the degree to which their provider
recommends tobacco-cessation treatment (implied recom-
mendation), perceptions of the “status quo” for hospital to-
bacco-cessation treatment (status quo bias), and perceptions
of paternalistic treatment by UKanQuit staff [13, 23, 33].
Intervention costs
We will prospectively track variable intervention costs.
Costs will include inpatient counselor services, post--
discharge counseling time, and initial pharmacotherapy
dispensed at baseline. During the 6-month follow-up
call, we will ask participants to recall their use of
pharmacotherapy after the initial supply. Personnel time
will be valued at Bureau of Labor Statistics
(www.bls.gov) wages plus benefits for an appropriately
trained health-promotion professional. Pharmacotherapy
costs will be based upon retail prices estimated from
on-line pharmacy websites. Intervention costs will be
tracked as they are incurred. We will exclude research
costs. We will not discount either costs or benefits.
Fidelity monitoring
Fidelity to the study protocol will be assessed by in-person
fidelity assessments during hospital consults. To assess
the quality of the intervention and control conditions, we
will assess the degree to which study staff accurately: (1)
provide brief advice and (2) perform the appropriate
intervention for OPT OUT versus OPT IN. Data on fidel-
ity will be entered into a RedCAP database and reported
back to study staff to encourage adherence to protocols.
Protection against risks
There are minimal risks in this study. Any emails used
to transmit study participant information will be
encrypted to protect the privacy of patients. Salivary
cotinine samples are noninvasive; samples will be labeled
with participants’ study ID numbers, rather than names,
to protect participants’ privacy. When collecting proxy
verification of smoking status, no information about the
patients’ participation in the trial will be provided to the
proxy besides the participants’ name and the fact that
they had nominated the proxy to provide verification of
smoking status at the end of a health-promotion study.
Standard language in our consent procedure assures
the participants of the confidential nature of the study.
Those who elect to participate will be clearly told that
they may withdraw from the study at any time without
jeopardizing current or future care at any medical facil-
ity. Potential participants will also be informed of alter-
native treatments (i.e., using other smoking-cessation
programs, purchasing nicotine gum, patches, or lozenges
from the pharmacy, obtaining a prescription for a nico-
tine inhaler, nasal spray, or other smoking-cessation
products from their physician). These standards are
strictly adhered to and monitored by the KUMC Institu-
tional Review Board. Only summaries of group data will
be reported in any publications or presentations, with no
identification of individuals. All records will be kept in
locked filing cabinets in offices that are kept locked
when unoccupied. Subject files will be kept in a secure
area, with access only by designated staff members (PI
and co-investigators).
Data management
Data management will follow procedures developed for
Enhancing Quitline Utilization among In-Patients
(EQUIP). UKanQuit service data, and survey data
collected by research assistants, will be directly entered
via tablet into REDCap. The project director will coord-
inate data retrieval from the EHR. The data manager will
conduct initial data cleaning, identifying and tagging any
crossovers, conversion into proper format for data ana-
lysis, and recoding using standard operating procedures.
All data will be imported into SAS for study analyses.
Cleaning and management routines (e.g., conversion of
birth dates to ages, logical checks for continuous vari-
ables, compliance with skip patterns, missing data codes)
will be conducted using SAS.
Data safety and monitoring plan
Due to the low level of risks involved in the proposed
study, a Data and Safety Monitoring Board (DSMB) will
not be necessary. The data and safety monitoring will be
overseen by the PI, Dr. Richter, and an annual progress
report will be provided to the Human Subjects Committee
of the University of Kansas Medical Center as well as the
NIH. The purpose of this data and safety monitoring plan
is to ensure the safety of study participants and the validity
of data in compliance with National Institutes of Health
(NIH) requirement of Data and Safety Monitoring for
Clinical Trials. This section outlines essential elements of
the Data Safety and Monitoring (DSM) plan for this
clinical trial.
Plans for assuring data accuracy and protocol compliance
Data management activities for this project will encom-
pass data entry, data cleaning, identifying and tagging any
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crossovers, conversion into proper format for data analysis
and recoding. In addition, a computer-based tracking
system will be developed to follow each patient and to
prompt the staff for the upcoming data collection point.
Data collection points for each subject will be calculated
from their initial date of contact. Data entry will be
performed on site under direction of the PI and the study
statistician. Keypunching routines will adhere to the code-
book specifications written by the team. Codebooks will
include variable formats (numeric/alpha), min/max ranges
and any skip patterns. Data will be double entered utiliz-
ing two separate databases and data entry personnel for
the two databases would be different. Both the databases
and the tracking system would be password protected for
security and maintenance of confidentiality. At the end of
each data entry period, data would be backed up onto a
storage unit. Checks built into the database will ensure
that individuals not meeting eligibility criteria are flagged
and excluded from data analysis.
Data sharing
This study will generate quantitative and qualitative data
from the randomized trial. The final quantitative dataset
will include self-reported demographic and behavioral
data from subjects. Because we collect data at multiple
time points from participants over the 6-month period
that each participant will be in the study, we will collect
identifying information. Prior to data sharing, we will
remove or convert all identifying information (date of
birth will be converted to age, date of admission and
discharge will be removed, and other identifiers will be
removed). There may remain the possibility of deductive
disclosure of subjects with unusual characteristics. Thus,
we will make the data and associated documentation
available to users under a data-sharing agreement that
provides for: (1) a commitment to using the data only
for research purposes and not to identify any individual
participant, (2) a commitment to securing the data using
appropriate computer technology, and (3) a commit-
ment to destroying or returning the data after analyses
are completed. Data will be saved as SAS or SPSS files,
saved to disk, and mailed to users.
Data analysis
Overview of hypotheses and analyses
The overall design is a randomized controlled trial
(RCT) with individual assignment to groups. Bayesian
analysis will drive participant allocation. Prior to out-
come analyses we will examine baseline data to evaluate
if randomization achieved equivalent groups. In addition,
we will conduct process, outcome, mediation, and cost
analyses.
Bayesian design
We will perform a prospective randomized comparative
effectiveness Bayesian adaptive design study [34]. Our end-
point is the percentage of patients with verified cessation at
1 month (4 weeks) post randomization. We will perform our
first planned interim analyses when we have endpoint data
on 400 patients. The arm that appears to be performing the
best will get more participants allocated to it in the subse-
quent randomization period. A new adaptive randomization
structure will be updated every 13 weeks, using up-to-date
outcome data, until the trial meets success or all 1000
subjects are consented. The main outcome analysis will use
an ITTapproach, with the denominator being all participants
randomized to the study. Data from patients we are unable
to reach at 1 month will be de-identified and included in
data analyses.




In addition, we provide “weakly informative” priors:
logit(θQj ) ~ N(0,100
2).
Using the endpoint data and the prior probabilities, we
then use Markov Chain Monte Carlo computations to
obtain the Bayesian posterior distributions for the end-
point (i.e., quitting). We will stop randomizing into the
comparative trial if the probability of a study arm having
maximum utility is greater than 0.9925. The arm having




2 ). The stop-
ping rule is mathematically P(MT > .9925). If a maximum
arm is not identified after 500 patients, this procedure
and accrual will continue until a maximum arm is iden-
tified or we enroll all 1000 patients. It is possible that we
will reach the maximum utility criterion before 1000
patients are consented. Should this occur, we will stop
the trial and begin outcome, cost, and mediation ana-
lyses in order to quickly disseminate findings.
After the maximum arm probability is evaluated, the
next round of patients is randomized using a formula
that favors the arm with the maximum quit rate, thus
taking advantage of the information gained from our in-
terim analyses. Using this formula, each arm is allocated
for the next patients to be enrolled in the jth arm pro-
portional to:




= njT þ 1
  
:
This type of allocation has more desirable properties
than simply using Pr(MjT = θ
Q
1 ). In other words, using
this approach will allow us to assign more patients to
the most promising arm, and fewer patients to the least.
Regardless of when the maximum arm probability cut
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point is reached, we will confirm this finding with a sub-
sequent analysis and evaluation (> .99) after all data
from all enrolled patients are obtained, as some will be
in the study when early success criteria are identified.
Projected quit rates
As defined in the 2012 Cochrane review of smoking cessa-
tion in hospitalized patients [35], across both study arms,
smokers who receive post-discharge support and medica-
tions will receive level-4 intensity treatment and smokers
who receive only inpatient brief counseling will receive
level-1 intensity treatment. Pooled quit rates are 10% for
level-1 intensity studies and 29% for level-4 intensity stud-
ies [35]. Based on EQUIP and other trials, we estimate
that 30% of OPT-IN participants will be ready to quit and
receive services [36, 37]. For OPT OUT, based on the
Inter99 trial and our pilot study on proactive quitline
counseling we estimate that 80% of patients will accept
services [38, 39]. We calculate the proposed quit rates
within each condition using the following formula:
½ðprop: receiving services  level 4 quit ratesÞ
þ prop: not receiving services  level 1 quit ratesÞ:ð
We estimate the quit rate to be 15.7% in the OPT-IN
group: [(.30 × .29) + (.70 × .10)] = .157. We estimate the
quit rate to be 25.2% in the OPT-OUT group:
[(.80 × .29) + (.20 × .10)] = .252.
Power, sample size, and trial duration
In accordance with guidelines for adaptive design power
analyses [34], we used simulated data to determine the
power, sample size, and anticipated duration of the
study. We created virtual responses for our “expected”
quit rates, another for “small but unlikely” quit rates,
and a third for “no differences” in quit rates. We per-
formed three sets of trial simulations (Table 4). Each set
involved many trial simulations that identified power
(the probability of success) in two scenarios—one for
early success (i.e., being able to stop randomization
early) and one for late success (i.e., upon enrolling all
1000 patients). While two of these combinations are very
unlikely to occur, we included all scenarios. First, under
the “expected” quit rates, we estimated (identified) that
92% of the simulated trials had early success, 3% late
success, and only 5% had incomplete results. Thus, this
scenario had 95% power. The average sample size of this
trial scenario was 625 patients with more than half (387)
in the better OPT-OUT arm. The average length of these
simulated trials was 98 weeks. Second, if there are “small
but unlikely” quit rates, we identified that 30% of the
simulated trials had early success, 5% had late success,
and 65% had incomplete results. This trial scenario had
35% power and the sample size of this trial scenario was
on average 903 with more than half (530) in the better
OPT-OUT arm. The average length of this trial scenario
was 142 weeks. Third, we examined the scenario that
serves as our null hypothesis. In this scenario there are
no differences in quit rates among the arms. The extent
to which this scenario is “successful” reflects our Type-I
error rate. For this scenario, we identified that 4% of the
simulated trials had early success, 1% late success. This
trial scenario produced an appropriate expected Type-I
error (α = .05). The sample size of this scenario on aver-
age was 986 patients, with about half (495) in the OPT-
OUT arm. The average length of the trials under this
scenario was 155 weeks—approximately 3 years of
recruitment. Hence, our maximal sample size of 1000,
in 3 years of recruitment, provides ample time and
participants to identify project outcomes under all
three scenarios.
Accrual (enrollment) patterns
Accrual patterns refer to how rapidly we enroll patients in
the trial. These are important to Bayesian adaptive designs
for determining the length of the trial. Based on accrual
patterns for EQUIP and other hospital studies conducted
by our team, and the sample size required for this trial, we
assume that the accrual patterns will follow a Poisson dis-
tribution with an average of 6.7 patients per week.
Accounting for missing data
For the main outcome analysis, in accordance with the
ITT principle, patients lost to follow-up will be consid-
ered smokers. We will also calculate main and secondary
outcomes using imputed data. Missing observations on
covariates will be handled through Bayesian posterior
predictive distributions with auxiliary variables, auxiliary
variables are variables that are not part of the analysis
model, yet are included as missing data correlates to
strengthen the assumption that missing covariates are
missing at random (MAR; missingness is independent of
the missing value) [40–42]. Assuming data are MAR,
analyses employed under the ITT principle are consid-
ered acceptable.
Sensitivity analyses
To explore the effects of assuming MAR when data are
actually MNAR (missing not at random) sensitivity
Table 4 Virtual response patterns for quit rate endpoint
OPT IN OPT OUT
Efficacy
No differences 15.7% 15.7% Both have equal quit rates
Small but unlikely 15.7% 20.0% OPT OUT is moderately better
Expected 15.7% 25.2% OPT OUT is better at expected
differences
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analyses will be conducted using either a pattern mixture
model or a selection model approach [42–45]. In addition,
we will conduct and report an exploratory pooled ITT
analysis to examine the effects of the Zelen design by cal-
culating overall quit rates assuming patients who were
dropped from the study due to failure to provide consent
were (a) smokers, (b) nonsmokers, or (c) MNAR.
Monitoring the impact of population drift and adaptive
randomization
There could be a drift in our population characteristics that
are related to outcome [46]. This is a problem for all trials,
whether they are equally or adaptively randomized. A re-
cent paper examined the effects of response probabilities
that changed over time due to this population drift, and
found that population drift had little effect on adaptive
randomization [47]. However, given our large dataset, we
may be in a unique position to contribute to understanding
how adaptive randomization might interact with population
drift. In order to determine whether drift occurs, we will
monitor the characteristics of the study population over
time—especially focusing on drift introduced (or magnified)
by adaptive changes in our random allocation rule. We will
focus on several factors that are known to be associated
with abstinence from smoking. These factors include ciga-
rettes per day, time to first cigarette, sex, age, and income
[48]. If we find that sample characteristics become unbal-
anced, we will adjust our outcome analyses to account for
this. In addition, in secondary outcome analyses, we will
track 1-month abstinence to determine whether rates chan-
ged over time. If we find significant changes in either popu-
lation characteristics or abstinence over time, we will
investigate whether (1) population drift, (2) temporal
changes in the randomization scheme, or (3) a combination
of the two had an effect on the proportion of patients who
quit smoking.
Analyses by aim
The main analyses for each aim are outlined below
(Table 5).
Aim 1. Hypothesis 1: among patients consented into the
trial, significantly more patients in OPT OUT will partici-
pate in counseling, use cessation medications, and be
abstinent from smoking at 1 month post randomization
compared to OPT IN. These analyses will involve two-
sample tests.
Aim 2. Hypothesis 2: significantly more smokers in
OPT OUT will be abstinent from smoking, and mediation
analyses will find that counseling participation, medication
use, and default-theory-based variables will partially or
fully explain the effect of OPT OUT on cessation at
6 months post randomization. After identifying a struc-
tural equation model that adequately fits the data for the
hypothesized associations between the intervention and 6-
month outcome, i.e., that Comparative Fit Index (CFI) > .9
and Root Mean Square Error of Approximation (RMSEA)
< .8, we will examine mediation using approaches based
on the work of MacKinnon et al. [49], Brown [50], and
Shrout and Bolger [51]. Our theoretical model (Fig. 1,
Significance) will guide our analysis.
Aim 2. Hypothesis 3: OPT OUT will be more cost-
ly—in terms of upfront costs—but will be more effective
than OPT IN. As a result, OPT OUT will be more cost--
effective from a provider perspective. We will conduct a
cost-effectiveness analysis to explicitly document the
relative costs and benefits of OPT OUT versus OPT IN.
Our cost analytic framework generally follows the guide-
lines adopted by the Centers for Disease Control (CDC)
in accordance with the Consensus Panel on Cost-effec-
tiveness in Health and Medicine [52–54]. We will divide
the analysis into two components: first, intervention-
only costs, and second, intervention plus short-term
(6 months or less) costs post discharge. The primary
cost-effectiveness analysis will be set up as an incremen-
tal cost-effectiveness ratio (ICER). Incremental cost-
effectiveness analysis identifies the marginal benefit of
switching from one intervention to the other and is the
ratio of the difference in costs divided by the difference
in effectiveness between the two study arms. The out-
come assessed will be biochemically or proxy-verified 7-
Table 5 Study hypotheses, measures, and analytic strategy
Purpose Variables Analytic strategy
Hypothesis 1: compared to OPT IN, significantly
more patients in OPT OUT will participate in
counseling, use cessation medications, and be
abstinent from smoking
Abstinence: treatment condition and 1-month
7-day point-prevalence abstinence
2-sample binomial test
Counseling: treatment condition and total
counseling time by 1 month
2-sample lognormal test
Medication: treatment condition and number
of days of medication use
2-sample Poisson test
Hypothesis 2: significantly more smokers in OPT
OUT will be abstinent from smoking, and mediation
analyses will partially or fully explain the effects
Treatment condition and 6-month and
• 7-day point-prevalence abstinence
• Default variables • Counseling/medication use
Bayesian structural equation
modeling with a logistic
outcome
Hypothesis 3: OPT OUT will be more costly but also
more effective than OPT IN
Treatment condition and 1-month abstinence
• Variable costs
Incremental cost/quit
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day point-prevalence abstinence. The ICER will indicate
the added cost per additional quitter OPT OUT versus
OPT IN, a metric that will allow comparisons to other
smoking-cessation economic studies. While the societal
perspective is recommended by current national guide-
lines, it requires quality-adjusted life years (QALYs) as
the denominator [52]. Since this is a short-term study,
we decided against attempting to estimate changes in
QALYs, and focus instead on cost per quit and incorpor-
ate costs from a health care system perspective (direct
costs only), comparable to a-priori cost analyses of
several clinical trials based in Kansas [55, 56]. In sensi-
tivity analyses, we will adjust wage rates upwards to the
national average. In order be able to generalize our find-
ings from this one clinical trial to other populations, we
will explore how the variation in counseling time and ef-
fectiveness influence the relative cost-effectiveness of the
treatment strategies. Our analyses will vary time and ef-




Missed opportunities for providing medications and
counseling for tobacco dependence has created a large
treatment gap. This study innovatively reframes the
rationale for this gap: what if low rates of treatment are
caused not by smokers’ lack of motivation to quit, but by
requiring patients to opt in to care? Viewed from this
perspective, the effects of screening for readiness on
tobacco-cessation treatment can be tested by changing
the way that treatment is offered. This study also identi-
fies a major rate-limiting step in access to tobacco-
cessation treatment. Regardless of what population, set-
ting, or approach is used to disseminate tobacco-
cessation treatment, as long as providers screen for
readiness, the majority of smokers will report that they
are not ready to quit—and that they will not receive
medications or counseling.
The modified Zelen design is a novel feature of this
trial, which will permit a true population-based study in
which all smokers, regardless of their level of motivation,
will be included in the study. By consenting patients
after random assignment and treatment, the study does
run the risk of dilution bias introduced by participants
refusing consent post randomization [22]. A recent com-
prehensive review of Zelen trials found that most trials
experience low dilution bias (single-digit percentages of
refusal to consent or crossover). This suggests that the
potential for recruiting a more representative and
generalizable sample greatly outweighs the dilution bias
introduced at the time of consent.
The Bayesian adaptive design approach is another
novel feature of this trial. It is a highly efficient and
ethical strategy for comparative effectiveness clinical trial
design because it allocates more patients to effective
treatments and can answer the research question earlier
than conventional designs [57, 58]. In this approach one
primary endpoint is used to drive the adaptive
randomization. This endpoint is compared across study
groups periodically, and more patients are randomized to
the stronger arm until a predetermined probability that
one arm has “maximum utility” is reached, which signals
the end of the comparative trial.
This trial will identify the impact of default tobacco-
cessation treatment, for an entire population of smokers,
on (1) use of medications and counseling and (2) cessation.
It will identify the costs and cost-effectiveness of changing
the default, and examine psychological mediators of change
based on decision theory. This contribution is significant
because it will definitively determine the impact of routinely
assessing smokers’ readiness to quit in real-world clinical
practice. Assessing readiness is an integral step in the “5
As” of tobacco-cessation treatment (Ask, Advise, Assess
[readiness to quit], Assist, Arrange) [3]. But the Assess step
is only supported by “C-level” evidence of effectiveness, as
there are no trials that establish that it has a positive impact
on cessation [3]. Indeed, we hypothesize that the Assess step
may actually reduce the number of smokers that receive
evidence-based treatment. If our hypothesis is confirmed, it
could transform the “5 A” approach and increase access to
treatment for the more than 30 million smokers that visit a
health care provider each year [59, 60].
Trial status
Recruitment of participants started on 12 September
2016 and at the time of submission of this manuscript,
enrollment is ongoing (Additional file 1).
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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